Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Researchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a ...

Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

While the exact number of people with chronic kidney disease in South Africa is unclear, estimates suggest it could be as ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

Glenmark launches Empagliflozin and combinations in India under Glempa brand, aiming to improve glycemic control and reduce ...

Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic ...

Glenmark Pharmaceuticals announced that it has launched generic Empagliflozin, a widely recognized SGLT2 inhibitor, in India.